AzTrials
AzTrials

Atopic DermatitisPhase 3AD UpNCT03568318

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

A Phase 3 study testing Upadacitinib and Topical corticosteroids (TCS) in people with Atopic Dermatitis, run by AbbVie at 193 sites in 24 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. Read more about this study

Who is it for?
Ages 12 to 75 years
Conditions the study is for
Atopic Dermatitis
What is being tested?
Upadacitinib and Topical corticosteroids (TCS)
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
1,533 participants
Where
193 sitesin 24 countries
Study dates
9 Aug 2018to 23 Oct 2030
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 to 75 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Body weight of ≥ 40 kg at Baseline Visit for participants ≥ 12 and < 18 years of age
  • Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years prior to Baseline Visit and subject meets Hanifin and Rajka criteria.
  • Active moderate to severe atopic dermatitis defined by Eczema Area and Severity Index (EASI) ≥ 16, validated Investigator's Global Assessment (vIGA) ≥ 3, ≥ 10% of body surface area (BSA) with AD involvement, and weekly average of daily Worst Pruritus numerical rating scale (NRS) ≥ 4.
  • Subject has applied a topical emollient (moisturizer) twice daily for at least 7 days before the Baseline Visit.
  • Documented history of inadequate response to topical corticosteroids or topical calcineurin inhibitor OR documented systemic treatment for AD within 6 months prior to Baseline Visit

Who cannot join

  • Prior exposure to any Janus kinase (JAK) inhibitor
  • Unable or unwilling to discontinue current atopic dermatitis (AD) treatments prior to the study
  • Requirement of prohibited medications during the study
  • Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions
  • Female subject who is pregnant, breastfeeding, or considering pregnancy during the study

Trial locations and contacts

193 sites in 24 countries.

193 sites in 24 countries

United States59 sites
  • ORA, Inc. /ID# 202824

    Andover, Massachusetts, 01810

  • Arlington Research Center, Inc /ID# 200559

    Arlington, Texas, 76011

  • Duplicate_University of Colorado Anchutz Medical Campus /ID# 202822

    Aurora, Colorado, 80045-2517

  • Bakersfield Derma & Skin Cance /ID# 200892

    Bakersfield, California, 93309

  • Mosaic Dermatology /ID# 200553

    Beverly Hills, California, 90211

  • Bexley Dermatology Research /ID# 200899

    Bexley, Ohio, 43209-2422

  • Total Skin and Beauty Derm Ctr /ID# 200548

    Birmingham, Alabama, 35205

  • Clinical Research Center AL /ID# 201865

    Birmingham, Alabama, 35209-6802

  • ACCEL Research Sites /ID# 213364

    Birmingham, Alabama, 35218

  • Clearlyderm Dermatology /ID# 207709

    Boca Raton, Florida, 33428

  • Skin Care Research, LLC /ID# 200812

    Boca Raton, Florida, 33486-2269

  • Advanced Clinical Research at Treasure Valley Dermatology & Skin Cancer Center /ID# 203628

    Boise, Idaho, 83713

  • Tufts Medical Center /ID# 200570

    Boston, Massachusetts, 02111-1552

  • Beth Israel Deaconess Medical Center /ID# 200545

    Boston, Massachusetts, 02215-5400

  • Colorado Center for Dermatology, PLLC /ID# 203626

    Centennial, Colorado, 80111-1724

  • Clin Res Inst of Michigan, LLC /ID# 208020

    Chesterfield, Michigan, 48047

  • Northwestern University Feinberg School of Medicine /ID# 201646

    Chicago, Illinois, 60611-2927

  • Michigan Center for Research Company /ID# 200560

    Clarkston, Michigan, 48346

  • Clinical Research of West Florida, Inc /ID# 203643

    Clearwater, Florida, 33765

  • The Ohio State University /ID# 200542

    Columbus, Ohio, 43210-1257

  • Florida Academic Centers Research and Education /ID# 200544

    Coral Gables, Florida, 33134

  • Psoriasis Treatment Center of Central New Jersey /ID# 200714

    East Windsor, New Jersey, 08520

  • Deaconess Clinic Downtown /ID# 201001

    Evansville, Indiana, 47713-1227

  • Rivergate Dermatology & Skin Care Center /ID# 201698

    Goodlettsville, Tennessee, 37072-2301

  • Center for Clinical Studies /ID# 200582

    Houston, Texas, 77004

  • Indiana University /ID# 200515

    Indianapolis, Indiana, 46202

  • University of California Irvine /ID# 200902

    Irvine, California, 92697-1385

  • Dartmouth-Hitchcock Medical Center /ID# 200918

    Lebanon, New Hampshire, 03756

  • University of Wisconsin - Madison /ID# 204933

    Madison, Wisconsin, 53715-1218

  • Advanced Dermatology and Skin Care Centre /ID# 213550

    Mobile, Alabama, 36605-3004

  • Stones River Dermatology /ID# 204962

    Murfreesboro, Tennessee, 37129-3194

  • Juva Skin and Laser Center /ID# 200997

    New York, New York, 10022-3204

  • Eastern Virginia Med School /ID# 200994

    Norfolk, Virginia, 23507-1627

  • Tory P Sullivan, MD PA /ID# 201174

    North Miami Beach, Florida, 33162-4708

  • Skin Specialists, PC /ID# 200573

    Omaha, Nebraska, 68144

  • Park Avenue Dermatology, PA /ID# 201012

    Orange Park, Florida, 32073

  • Epiphany Dermatology of Kansas LLC /ID# 203026

    Overland Park, Kansas, 66210

  • Alliance Dermatology and MOHs Center, PC /ID#200540

    Phoenix, Arizona, 85032

  • Arizona Research Center, Inc. /ID# 200546

    Phoenix, Arizona, 85053-4061

  • University of Pittsburgh MC /ID# 206057

    Pittsburgh, Pennsylvania, 15260

  • Oregon Dermatology and Research Center /ID# 200601

    Portland, Oregon, 97210

  • Rhode Island Hospital /ID# 200566

    Providence, Rhode Island, 02903

  • MediSearch Clinical Trials /ID# 201006

    Saint Joseph, Missouri, 64506

  • Advanced Clinical Research - Woseth Dermatology /ID# 213745

    Salt Lake City, Utah, 84117-4209

  • Progressive Clinical Research /ID# 201582

    San Antonio, Texas, 78229

  • Therapeutics Clinical Research /ID# 200593

    San Diego, California, 92123

  • Clear Dermatology & Aesthetics Center /ID# 201257

    Scottsdale, Arizona, 85255-4134

  • Dermatology Associates of Seattle /ID# 200717

    Seattle, Washington, 98101

  • Dermatology Physicians of Connecticut /ID# 201004

    Shelton, Connecticut, 06484-6211

  • Northshore University Health System Dermatology Clinical Trials Unit /ID# 200556

    Skokie, Illinois, 60077

  • Stanford University /ID# 200597

    Stanford, California, 94305

  • Precision Clinical Research /ID# 208734

    Sunrise, Florida, 33351-7311

  • J. Schwartz, MD, PLLC /ID# 202122

    Troy, New York, 12180-2323

  • University of Arizona /ID# 201059

    Tucson, Arizona, 85719

  • Vital Prospects Clinical Research Institute, PC /ID# 200901

    Tulsa, Oklahoma, 74136-7049

  • AAPRI Clinical Research /ID# 221134

    Warwick, Rhode Island, 02886-2876

  • Center for Clinical Studies - Webster TX /ID# 203186

    Webster, Texas, 77598

  • Duplicate_Western States Clinical Research, Inc. /ID# 201702

    Wheat Ridge, Colorado, 80033-2896

  • DuPage Medical Group /ID# 202065

    Wheaton, Illinois, 60189-3801

Other trials in United States

Canada17 sites
  • Kirk Barber Research, CA /ID# 200329

    Calgary, Alberta, T2G 1B1

  • Dermatology Research Institute Inc. /ID# 200341

    Calgary, Alberta, T2J 7E1

  • Alberta DermaSurgery Centre /ID# 205674

    Edmonton, Alberta, T6G 1C3

  • Eastern Canada Cutaneous Resea /ID# 200335

    Halifax, Nova Scotia, B3H 1Z2

  • Lynderm Research Inc. /ID# 200338

    Markham, Ontario, L3P 1X2

  • DermEdge Research Inc. /ID# 200337

    Mississauga, Ontario, L5H 1G9

  • CHU Sainte-Justine /ID# 206013

    Montreal, Quebec, H3T 1C5

  • The Centre for Clinical Trials /ID# 205404

    Oakville, Ontario, L6J 7W5

  • Angela Montgomery Medicine Professional Corporation /ID# 212653

    Ottawa, Ontario, K1H 7X3

  • SKIN Centre for Dermatology /ID# 200331

    Peterborough, Ontario, K9J 5K2

  • Centre de recheche dermatologique du Quebec Metropolitain /ID# 205403

    Québec, Quebec, G1V 4X7

  • The Center For Dermatology /ID# 205409

    Richmond Hill, Ontario, L4B 1A5

  • Dre Angelique Gagne-Henley M.D. inc. /ID# 200330

    Saint-Jérôme, Quebec, J7Z 7E2

  • Karma Clinical Trials /ID# 200339

    St. John's, Newfoundland and Labrador, A1A 4Y3

  • Toronto Research Centre /ID# 205411

    Toronto, Ontario, M3H 5Y8

  • Research Toronto /ID# 205410

    Toronto, Ontario, M4W 2N4

  • XLR8 Medical Research /ID# 205405

    Windsor, Ontario, N8W 1E6

Other trials in Canada

Japan16 sites
  • Hiramoto skin clinic /ID# 204048

    Amagasaki-shi, Hyōgo, 661-0953

  • Juntendo University Hospital /ID# 202888

    Bunkyo-ku, Tokyo, 113-8431

  • Medical Corporation Matsuo Clinic /ID# 202312

    Fukuoka, Fukuoka, 819-0373

  • Osaka Habikino Medical Center /ID# 204243

    Habikino-shi, Osaka, 583-8588

  • Tokai University Hachioji Hospital /ID# 201711

    Hachioji-shi, Tokyo, 192-0032

  • Hiroshima University Hospital /ID# 201914

    Hiroshima, Hiroshima, 734-8551

  • Maruyama Dermatology Clinic /ID# 202350

    Koto-ku, Tokyo, 136-0074

  • University Hospital Kyoto Prefectural University of Medicine /ID#258604

    Kyoto, Kyoto, 602-8566

  • Kyoto University Hospital /ID# 201654

    Kyoto, Kyoto, 606-8507

  • Chukyo Hospital /ID# 202311

    Nagoya, Aichi-ken, 457-8510

  • National Hospital Organization Sagamihara National Hospital /ID# 201658

    Sagamihara-shi, Kanagawa, 252-0392

  • Medical Corporation Kojinkai Sapporo Skin Clinic /ID#258665

    Sapporo, Hokkaido, 060-0063

  • Tohoku University Hospital /ID# 206322

    Sendai, Miyagi, 9808574

  • Jichi Medical University Hospital /ID# 201913

    Shimotsuke-shi, Tochigi, 329-0498

  • Yamate Dermatological Clinic /ID# 202130

    Shinjuku-ku, Tokyo, 1690075

  • Queens Square Medical Center dermatology allergology /ID# 203850

    Yokohama, Kanagawa, 220-6208

Other trials in Japan

Germany10 sites
  • Universitaetsklinikum Bonn /ID# 202092

    Bonn, 53127

  • Universitaetsklinikum Frankfurt /ID# 202095

    Frankfurt am Main, Hesse, 60590

  • TFS Trial Form Support GmbH /ID# 202096

    Hamburg, 20537

  • Medizinische Hochschule Hannover /ID# 202098

    Hanover, 30625

  • Universitaetsklinik Heidelberg /ID# 202097

    Heidelberg, Baden-Wurttemberg, 69120

  • Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 202256

    Kiel, Schleswig-Holstein, 24105

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz /ID# 205194

    Mainz, 55131

  • Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 202093

    Munich, 81675

  • Universitaetsklinikum Muenster /ID# 202094

    Münster, North Rhine-Westphalia, 48149

  • CMS3 Company for Medical Study /ID# 205195

    Selters, Rhineland-Palatinate, 56242

Other trials in Germany

China9 sites
  • Chinese PLA General Hospital /ID# 206786

    Beijing, Beijing Municipality, 100853

  • Beijing Friendship Hospital /ID# 207434

    Beijing, 100032

  • Xiangya Hospital Central South University /ID# 207510

    Changsha, 410008

  • Sun Yat-sen Memorial Hospital of Sun Yat-sen University /ID# 206728

    Guangzhou, Guangdong, 510120

  • The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 207132

    Hangzhou, Zhejiang, 310006

  • The second Affiliated hospital of Zhejiang University school of Medicine /ID# 207442

    Hangzhou, Zhejiang, 310009

  • Huashan Hospital of Fudan University /ID# 207437

    Shanghai, 200040

  • The First Hospital of China Medical University /ID# 209840

    Shenyang, Liaoning, 110001

  • Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 206669

    Wuhan, Hubei, 430022

Other trials in China

United Kingdom7 sites
  • NHS Tayside /ID# 202081

    Dundee, Scotland, DD2 1UB

  • NHS Greater Glasgow and Clyde /ID# 201374

    Glasgow, Scotland, G12 0XH

  • Leeds Teaching Hospitals NHS Trust /ID# 201106

    Leeds, LS9 7TF

  • Barts Health NHS Trust /ID# 201044

    London, London, City of, E1 2ES

  • Guy's and St Thomas' NHS Foundation Trust /ID# 201193

    London, London, City of, SE1 9RT

  • Guy's and St Thomas' NHS Foundation Trust /ID# 204642

    London, London, City of, SE1 9RT

  • Oxford University Hospitals NHS Foundation Trust /ID# 202052

    Oxford, Oxfordshire, OX3 9DU

Other trials in United Kingdom

Greece6 sites
  • 401 GSNA - 401 Army General Hospital /ID# 211963

    Athens, Attica, 11525

  • Children's Hosp P. A. Kyriakou /ID# 217573

    Athens, Attica, 11527

  • University General Hospital Attikon /ID# 201126

    Athens, Attica, 12462

  • General Hospital Andreas Syggros /ID# 201123

    Athens, Attica, 16121

  • Papageorgiou General Hospital Thessaloniki /ID# 202392

    Stavroupoli (Thessalonikis), Thessaloniki, 55536

  • Thessaloniki Hospital of Skin and Venereal Diseases /ID# 201124

    Thessaloniki, 54643

Other trials in Greece

Italy6 sites
  • Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 200690

    Ancona, 60126

  • A.O.U. Policlinico G. Rodolico S.Marco- Presidio G.Rodolico /ID# 200742

    Catania, 95123

  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 200744

    Milan, 20122

  • Azienda Ospedaliera Universitaria Federico II /ID# 200751

    Naples, 80131

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 203014

    Rome, Lazio, 00168

  • Istituto Clinico Humanitas /ID# 200739

    Rozzano, Milano, 20089

Other trials in Italy

Spain6 sites
  • Hospital General Universitario Alicante /ID# 200873

    Alicante, 03010

  • Hospital Santa Creu i Sant Pau /ID# 201325

    Barcelona, 08041

  • Hospital Universitario de la Princesa /ID# 201517

    Madrid, 28006

  • Hospital Universitario 12 de Octubre /ID# 201135

    Madrid, 28041

  • Hospital Universitario La Paz /ID# 205438

    Madrid, 28046

  • Hospital Universitario de Puerto Real /ID# 200875

    Puerto Real, Cadiz, 11510

Other trials in Spain

Australia5 sites
  • Fremantle Dermatology /ID# 205306

    Fremantle, Western Australia, 6160

  • St George Dermatology & Skin Cancer Centre /ID# 204788

    Kogarah, New South Wales, 2217

  • Royal North Shore Hospital /ID# 204639

    St Leonards, New South Wales, 2065

  • Westmead Hospital /ID# 205682

    Westmead, New South Wales, 2145

  • Veracity Clinical Research /ID# 204793

    Woolloongabba, Queensland, 4102

Other trials in Australia

France5 sites
  • Hopital Saint-Andre /ID# 206129

    Bordeaux, 33075

  • AP-HM - Hopital de la Timone /ID# 206128

    Marseille, Bouches-du-Rhone, 13385

  • Chu de Nice-Hopital L'Archet Ii /Id# 205780

    Nice, Alpes-Maritimes, 06200

  • Polyclinique Courlancy /ID# 201537

    Reims, 51100

  • CHRU Tours - Hopital Gatien de Clocheville /ID# 218209

    Tours, Centre-Val de Loire, 37044

Other trials in France

Hungary5 sites
  • Debreceni Egyetem Klinikai Kozpont /ID# 201765

    Debrecen, Hajdú-Bihar, 4032

  • Derma-B Egeszsegugyi es Szolgaltato Kft. /ID# 217866

    Debrecen, 4031

  • Oroshazi Korhaz /ID# 203525

    Orosháza, Bekes County, 5900

  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont /ID# 204144

    Szeged, Csongrád megye, 6725

  • Allergo-Derm Bakos Kft. /ID# 205361

    Szolnok, 5000

Other trials in Hungary

Israel5 sites
  • HaEmek Medical Center /ID# 201958

    Afula, 1834111

  • Soroka University Medical Center /ID# 206652

    Beersheba, Southern District, 8443901

  • Rabin Medical Center /ID# 201959

    Petah Tikva, 4941492

  • The Chaim Sheba Medical Center /ID# 201611

    Ramat Gan, Tel Aviv, 5265601

  • Tel Aviv Sourasky Medical Center /ID# 201608

    Tel Aviv, Tel Aviv, 6423906

Other trials in Israel

Austria4 sites
  • Medizinische Universitaet Innsbruck /ID# 210897

    Innsbruck, Tyrol, 6020

  • Ordensklinikum Linz GmbH Elisabethinen /ID# 209567

    Linz, Upper Austria, 4010

  • Kepler Universitaetsklinikum GmbH /ID# 201075

    Linz, Upper Austria, 4021

  • Medizinische Universitaet Wien /ID# 201080

    Vienna, State of Vienna, 1090

Other trials in Austria

Belgium4 sites
  • UZ Gent /ID# 202030

    Ghent, Oost-Vlaanderen, 9000

  • UZ Brussel /ID# 203557

    Jette, Brussels Capital, 1090

  • IMTR - Grand Hopital de Charleroi /ID# 202029

    Loverval, 6280

  • UCL Saint-Luc /ID# 202028

    Woluwe-Saint-Lambert, Brussels Capital, 1200

Other trials in Belgium

Czechia4 sites
  • Fakultni nemocnice Plzen /ID# 202044

    Pilsen, 305 99

  • Sanatorium profesora Arenbergera /ID# 202082

    Prague, 110 00

  • Duplicate_Vseobecna Fakultni Nemocnice /ID# 205248

    Prague, 128 08

  • Vseobecna fakultni nemocnice v Praze /ID# 202045

    Prague, 128 08

Other trials in Czechia

Netherlands4 sites
  • Academisch Medisch Centrum /ID# 202193

    Amsterdam, 1105 AZ

  • Universitair Medisch Centrum Groningen /ID# 202195

    Groningen, 9713 GZ

  • Erasmus Medisch Centrum /ID# 202196

    Rotterdam, South Holland, 3015 GD

  • Universitair Medisch Centrum Utrecht /ID# 202194

    Utrecht, 3584 CX

Other trials in Netherlands

Norway4 sites
  • Haukeland University Hospital /ID# 201152

    Bergen, Hordaland, 5021

  • Universitetssykehuset N-Norge, Harstad /ID# 201269

    Harstad, Troms, 9406

  • Rikshospitalet OUS HF /ID# 201271

    Oslo, 0450

  • Universitetssykehuset N-Norge, Tromso /ID# 201270

    Tromsø, Troms, 9019

Other trials in Norway

Slovakia4 sites
  • Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica /ID# 204372

    Banská Bystrica, 975 17

  • Univerzitna nemocnica Martin /ID# 203851

    Martin, 036 01

  • Fakultna nemocnica s poliklinikou Nove Zamky /ID# 204240

    Nové Zámky, 940 34

  • Fakultna nemocnica s poliklinikou J.A. Reimana Presov /ID# 204373

    Prešov, 081 01

Other trials in Slovakia

Sweden4 sites
  • Sahlgrenska University Hospital /ID# 201274

    Gothenburg, Västra Götaland County, 413 46

  • Skane University Hospital Lund /ID# 201244

    Lund, Skåne County, SE 221 41

  • Sodersjukhuset /ID# 201242

    Stockholm, 118 83

  • Karolinska University Hospital /ID# 201243

    Stockholm, 171 76

Other trials in Sweden

Ireland3 sites
  • South Infirmary Victoria University Hospital /ID# 201079

    Cork, T12 X23H

  • St James Hospital /ID# 201118

    Dublin, Dublin, D08 NHY1

  • University Hospital Waterford /ID# 201253

    Waterford, X91 ER8E

Other trials in Ireland

Puerto Rico3 sites
  • Dr. Samuel Sanchez PSC /ID# 202002

    Caguas, 00727

  • Clinical Research Puerto Rico /ID# 203644

    San Juan, 00909

  • GCM Medical Group PSC - Hato Rey /ID# 202003

    San Juan, 00917-3104

Other trials in Puerto Rico

Hong Kong2 sites
  • Prince of Wales Hospital /ID# 205152

    Hong Kong, 999077

  • Queen Mary Hospital /ID# 205146

    Hong Kong, 999077

Other trials in Hong Kong

New Zealand1 site
  • Clinical Trials NZ /ID# 205336

    Hamilton, 3204

Other trials in New Zealand

About this study

Official title: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

Read the detailed description

This study includes a 35-day screening period, a 16-week double-blind period, a blinded extension period up to Week 260, a blinded Long-term Extension (LTE) Period after Week 260 to Week 524, and a 30-day follow-up visit. Participants who meet eligibility criteria in the Main Study will be randomly assigned in a 1:1:1 ratio to receive upadacitinib 15 mg, upadacitinib 30 mg, or placebo once daily, in combination with topical corticosteroids.

Upon completion of enrollment of 810 participants in the Main Study, a supplemental study will continue to enroll adolescent participants (Adolescent Sub-study) until a total of 180 adolescent participants are enrolled in the overall study (Main Study + Adolescent Sub-study).

Approximately 1000 participants from M16-045 or M18-891 and approximately 500 participants from M16-047 will have the opportunity to enroll into the blinded Long-Term Extension (LTE) period (Week 260 - Week 524) after reaching Week 260 in their respective studies.

Randomization for the Main Study will be stratified by Baseline disease severity (validated Investigator Global Assessment Scale for Atopic Dermatitis [vIGA-AD] score of moderate [3] versus severe [4]), by geographic region (US/Puerto Rico/Canada, Japan, China, and Other), and by age (adolescent [ages 12 to 17] versus adult [ages 18 to 75]). The separate randomization for the Adolescent Sub-study will be stratified by Baseline disease severity (moderate [vIGA-AD 3] versus severe [vIGA-AD 4]) and by geographic region (US/Puerto Rico/Canada and Other).

At Week 16 of both the Main Study and the Adolescent Sub-study, participants in the placebo group will be re-randomized in a 1:1 ratio to receive daily oral doses of upadacitinib 30 mg or upadacitinib 15 mg in the blinded extension period, and participants originally randomized to upadacitinib will continue upadacitinib in the extension period at the same dose. For the Main Study, the re-randomization will be stratified by Eczema Area and Severity Index (EASI) 50 responder status (Yes/No), by geographic region (US/Puerto Rico/Canada, Japan, China, and Other) and by age (adolescent [ages 12 to 17] versus adult [ages 18 to 75]). For the Adolescent Sub-study, the re-randomization will be stratified by EASI 50 responder (Yes/No) and by geographic region (US/Puerto Rico/Canada and Other).

Starting at Week 4, rescue treatment for AD may be provided at the discretion of the investigator if medically necessary The Primary Analysis for the Main Study will be conducted after all ongoing participants have completed Week 16. In addition, a Primary Analysis for the adolescent population (including the adolescent participants from the Main Study and the Adolescent Sub-study) will be conducted after all ongoing adolescent participants have completed Week 16.

Being tested
Placebo, Upadacitinib, Topical corticosteroids (TCS)
Keywords
Atopic Dermatitis, Upadacitinib
Medical subject headings
Dermatitis, Atopic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PlaceboDrug

    Tablets taken orally once a day

  • UpadacitinibDrug

    Also called ABT-494, RINVOQ™

    Tablets taken orally once a day

  • Topical corticosteroids (TCS)Drug

    Topical corticosteroids will be applied in a stepdown regimen, starting with medium potency once daily to areas with active lesions until lesions are clear or almost clear, or for 3 consecutive weeks, whichever is shorter; then low potency topical corticosteroids once daily. If lesions return or persist, this step-down approach will be repeated until lesion resolution or evidence of local or systemic topical corticosteroids toxicity.

    Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as low potency topical corticosteroid.

Study groups in NCT03568318
Study groupRoleWhat they receive
Placebo / Upadacitinib + Topical CorticosteroidsPlacebo comparatorParticipants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
Receives: Drug: Placebo; Drug: Upadacitinib; Drug: Topical corticosteroids (TCS)
Upadacitinib 15 mg QD + Topical CorticosteroidsExperimentalParticipants will receive upadacitinib 15 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
Receives: Drug: Upadacitinib; Drug: Topical corticosteroids (TCS)
Upadacitinib 30 mg QD + Topical CorticosteroidsExperimentalParticipants will receive upadacitinib 30 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
Receives: Drug: Upadacitinib; Drug: Topical corticosteroids (TCS)
Long-Term ExtensionExperimentalParticipants who reach Week 260 in Studies M16-045, M18-891, and M16-047 will have the opportunity to roll over into the blinded LTE period of M16-047 to continue receiving the same daily dose of upadacitinib for up to Week 524.
Receives: Drug: Upadacitinib; Drug: Topical corticosteroids (TCS)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

    The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Measured: Baseline and Week 16

  2. Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16

    The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale:

    • 0 - Clear: No inflammatory signs of AD;
    • 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification;
    • 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting;
    • 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present;
    • 4 - Severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present.

    Measured: Baseline and Week 16

Secondary outcomes (22)
  1. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Measured: Baseline (last available rolling average before the first dose of study drug) and Week 16

  2. Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

    The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Measured: Baseline and Week 16

  3. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Measured: Baseline (last available rolling average before the first dose of study drug) and Week 4

  4. Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 4

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

    The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

    Measured: Baseline and Week 4

  5. Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

    The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

    Measured: Baseline and Week 2

  6. Main Study: Percentage of Participants Achieving an EASI 90 Response at Week 4

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

    The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Measured: Baseline and Week 4

  7. Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored from 0 [none], to 3 [severe]) for redness, thickness, scratching, and lichenification.

    The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    The percentage of participants with an EASI 100 response at Week 16 was pre-specified as a ranked secondary endpoint for participants in the Upadacitinib 30 mg + Topical Corticosteroids group versus Placebo + Topical Corticosteroids group only.

    Measured: Baseline and Week 16

  8. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Measured: Baseline (last available rolling average before the first dose of study drug) and Week 1

  9. Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.

    Measured: Baseline (last available rolling average before the first dose of study drug) and Week 16

  10. Main Study: Percent Change From Baseline in EASI Score at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1)] moderate [2], or severe [3]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema).

    The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

    Measured: Baseline and Week 16

  11. Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

    The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

    Measured: Baseline and Week 16

  12. Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16

    The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale:

    • 0 - Clear: No signs of AD;
    • 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification;
    • 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting;
    • 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting;
    • 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.

    Measured: Baseline and Week 16

  13. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Measured: Baseline (last available rolling average before the first dose of study drug) and Week 16

  14. Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

    The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.

    Measured: Baseline and Week 16

  15. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Measured: Baseline (last available rolling average before the first dose of study drug) and Week 4

  16. Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 4

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

    The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

    Measured: Baseline and Week 4

  17. Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

    The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

    Measured: Baseline and Week 2

  18. Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 4

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1], moderate [2], or severe [3]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema).

    The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.

    Measured: Baseline and Week 4

  19. Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16

    EASI is used to measure the extent and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. and the severity score is calculated as the sum of the intensity scores (scored from 0 [none], to 3 [severe]) for redness, thickness, scratching, and lichenification.

    The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    An EASI 100 response is defined as a 100% reduction (improvement) from Baseline in EASI score.

    The percentage of participants with an EASI 100 response at Week 16 was pre-specified as a secondary endpoint for participants in the Upadacitinib 30 mg + TCS group versus Placebo + TCS group only.

    Measured: Baseline and Week 16

  20. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Measured: Baseline (last available rolling average before the first dose of study drug) and Week 1

  21. Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.

    Measured: Baseline (last available rolling average before the first dose of study drug) and Week 16

  22. Adolescents: Percent Change From Baseline in EASI Score at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none [0], mild [1)] moderate [2], or severe [3]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema).

    The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

    Measured: Baseline and Week 16

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jun 2018
  2. Study start9 Aug 2018
  3. Primary completion16 Feb 2021
  4. Study completion23 Oct 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
1,533 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03568318
Sponsor's protocol ID
M16-047
Other IDs
2017-005126-37, 2017
Acronym
AD Up
Status last verified
Sep 2025
First submitted
14 Jun 2018
Last updated
23 Dec 2025
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Expanded access
Available

Publications

  • Silverberg JI, Prajapati VH, Abraham S, Irvine AD, Gooderham MJ, Guttman-Yassky E, Tanizaki H, Rademaker M, Chen SH, Moreira A, Ta R, Lee WJ, Eyerich K. Achieving Minimal Disease Activity in Atopic Dermatitis Is Associated with Fewer Flares, Reduced Healthcare Resource Utilization, and Improved Disease Control: Analysis from the Real-World MEASURE-AD Study. Dermatol Ther (Heidelb). 2026 Jul 30. doi: 10.1007/s13555-026-01865-0. Online ahead of print.

    PubMed 42530735
  • Irvine AD, Prajapati VH, Guttman-Yassky E, Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Gold LFS, de Bruin-Weller M, Bieber T, Kabashima K, Rosmarin D, Sancho C, Calimlim BM, Grada A, Yang Y, Wu X, Levy G, Raymundo EM, Teixeira HD, Silverberg JI. Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks. Am J Clin Dermatol. 2025 Nov;26(6):1003-1016. doi: 10.1007/s40257-025-00975-3. Epub 2025 Sep 3.

    PubMed 40900410
  • Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28.

    PubMed 40875187
  • Paller AS, Mendes-Bastos P, Siegfried E, Eichenfield LF, Soong W, Prajapati VH, Lio P, Simpson EL, Raymundo EM, Suravaram S, Hu X, Yang Y, Huang X, Calimlim BM, Platt AM, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks. JAMA Dermatol. 2024 Dec 1;160(12):1304-1313. doi: 10.1001/jamadermatol.2024.3696.

    PubMed 39441580
  • Silverberg JI, Leshem YA, Calimlim BM, McDonald J, Litcher-Kelly L. Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS). Curr Med Res Opin. 2023 Oct;39(10):1289-1296. doi: 10.1080/03007995.2023.2251883. Epub 2023 Sep 13.

    PubMed 37691437
  • Thyssen JP, Thaci D, Bieber T, Gooderham M, de Bruin-Weller M, Soong W, Kabashima K, Barbarot S, Luna PC, Xu J, Hu X, Liu Y, Raymundo EM, Calimlim BM, Nduaka C, Gamelli A, Simpson EL. Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1871-1880. doi: 10.1111/jdv.19232. Epub 2023 Jun 21.

    PubMed 37247226
  • Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, Lio P, Thyssen JP, Simpson EL, Platt AM, Raymundo EM, Liu J, Calimlim BM, Huang X, Gu Y, Hu X, Yang Y, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials. JAMA Dermatol. 2023 May 1;159(5):526-535. doi: 10.1001/jamadermatol.2023.0391.

    PubMed 37043227
  • Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735.

    PubMed 36754548
  • Silverberg JI, Simpson EL, Calimlim BM, Litcher-Kelly L, Li X, Sun X, Leshem YA. Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS). Dermatol Ther (Heidelb). 2022 Dec;12(12):2817-2827. doi: 10.1007/s13555-022-00836-5. Epub 2022 Nov 4.

    PubMed 36333616
  • Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, Simpson EL, Vigna N, Teixeira HD, Barbarot S. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022 Oct;87(4):784-791. doi: 10.1016/j.jaad.2022.06.012. Epub 2022 Jun 15.

    PubMed 35714786
  • Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Werfel T, Zeng J, Huang X, Hu X, Hendrickson BA, Ladizinski B, Chu AD, Silverberg JI. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21.

    PubMed 34023009

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Upadacitinib and Topical corticosteroids (TCS) in people with Atopic Dermatitis, run by AbbVie at 193 sites in 24 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 23 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 193 sites in United States, Canada, Japan, Germany, China and 19 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 31 Mar 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 (time frame: Baseline and Week 16). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03568318, which also lists 11 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in